MedTrace Logo

GISEL:Registry of Breast Cancer Patients Treated With ECT

NCT06683404 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 205

Last updated 2024-11-12

No results posted yet for this study

Summary

Electrochemotherapy (ECT) is a safe skin-directed treatment for cancer which combines drug treatment with short electric pulses to the tumor. The procedure lasts 20-40 minutes and is generally performed under sedation. It generally allows for a fast recovery with low discomfort.

The aims of this study are to find out how well ECT works in patients with breast cancer that has spread to the skin (cutaneous metastases), and to find out which patients have the best response to the treatment.

Conditions

Interventions

DEVICE

Electrochemotherapy (ECT)

Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane induced by the local administration of electrical impulses (electroporation). ECT represents an effective therapy for loco-regional control of this disease.

DRUG

Bleomycin

Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane

Sponsors & Collaborators

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-22
Primary Completion
2021-10-21
Completion
2022-12-10

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06683404 on ClinicalTrials.gov